Singapore markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.59-0.13 (-1.02%)
At close: 04:00PM EST
12.42 -0.17 (-1.35%)
After hours: 06:59PM EST

Coherus BioSciences, Inc.

333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
United States
650 649 3530
https://www.coherus.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees334

Key executives

NameTitlePayExercisedYear born
Mr. Dennis M. LanfearChairman, Pres & CEO1.82M547.14k1955
Mr. Vladimir VexlerChief Scientific Officer768.47k919.67k1958
Mr. McDavid StilwellChief Financial OfficerN/AN/A1971
Mr. Richard L. HameisterChief Technical OfficerN/AN/AN/A
Mr. Thomas F. FitzpatrickChief Legal OfficerN/AN/AN/A
Mr. Chris ThompsonExec. VP of SalesN/AN/AN/A
Ms. Rebecca SunshineExec. VP of HRN/AN/A1963
Dr. Barbara K. Finck M.D.Acting Chief Medical OfficerN/AN/A1947
Mr. Michael A. FlemingChief Strategy OfficerN/AN/AN/A
Mr. Michael ChenSr. VP of Commercial Analytics & TradeN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Corporate governance

Coherus BioSciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.